Recent News

• 04.23.2025 - Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
• 04.23.2025 - Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
• 04.04.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.04.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.11.2025 - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
• 03.11.2025 - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Recent Filings

• 04.18.2025 - PRE 14A Other preliminary proxy statements
• 04.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - 8-K Current report
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - S-3 Registration statement under Securities Act of 1933
• 03.11.2025 - 8-K Current report
• 03.11.2025 - S-8 Securities to be offered to employees in employee benefit plans